Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article

The normal biological wound healing process consists of three precisely and highly programmed phases that require optimal conditions including internal and external factors. Any negative factors that disrupt the sequence or time frame of the healing mechanism can result in a non-healing wound or chr...

Full description

Saved in:
Bibliographic Details
Published in:Toxins Vol. 14; no. 6; p. 406
Main Authors: Winayanuwattikun, Waranaree, Vachiramon, Vasanop
Format: Journal Article
Language:English
Published: Basel MDPI AG 01.06.2022
MDPI
Subjects:
Amputation
Biological activity
BoNT-A
Botulinum toxin
Botulinum toxin type A
Chronic illnesses
Dosage and administration
Ischemia
Medical research
Medicine, Experimental
Muscle contraction
Muscles
neuromodulators
neurotoxin
Neurotoxins
Pain
Pressure ulcers
Raynaud’s phenomenon
Review
Skin
Spasticity
Toxins
Ulcers
wound
Wound healing
Thailand
ISSN:2072-6651, 2072-6651
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The normal biological wound healing process consists of three precisely and highly programmed phases that require optimal conditions including internal and external factors. Any negative factors that disrupt the sequence or time frame of the healing mechanism can result in a non-healing wound or chronic ulcers. Botulinum neurotoxin A (BoNT-A) which is generally known as anti-contraction of muscles has been reported as a successful treatment in various types of chronic ulcers. The aim of this study is to review the outcome of treatment with BoNT-A for chronic skin ulcers. The results demonstrated some positive effects of BoNT-A on chronic ulcers. Ischemic ulcers secondary to Raynaud’s phenomenon seem to be the most promising type of ulcers that have benefited from BoNT-A. The rationale behind using BoNT-A to fasten the wound healing process is also discussed. Further clinical trial studies should be conducted to affirm the efficacy of wound healing using BoNT-A administration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2072-6651
2072-6651
DOI:10.3390/toxins14060406